UPDATE: Wunderlich Securities Raises Price Target on DexCom to $15

According to Wunderlich Securities, DexCom DXCM price target is raised to $15. Wunderlich Securities said that DexCom, Inc. (DXCM) formally reported its Q4 results, following a positive pre-announcement in January. “The company will formally file for FDA approval by the end of Q1 or in early Q2, and appears to be on an increasingly visible track toward FDA approval in late 2012/early 2013.” DexCom closed yesterday at $11.19.